CAPSTONE INVESTMENT ADVISORS, LLC
Position in BCRX — Biocryst Pharmaceuticals Inc
CIK 1426196
NEW YORK, NY
Position in BCRX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$281,354
+$142,017 QoQ
Shares Held
29,554
+61.0% QoQ
Ownership
0.012%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2023
5 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in BCRX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026CAPSTONE INVESTMENT ADVISORS, LLC holds $5,128,141 across 6 Drug Manufacturers - Specialty & Generic names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
35,180 | $2,528,034 | |
| 2 | ANIP |
Ani Pharmaceuticals Inc
|
11,150 | $922,997 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
1,123 | $608,475 | |
| 4 | HIMS |
Hims & Hers Health, Inc.
|
13,568 | $470,402 | |
| 5 | SUPN |
Supernus Pharmaceuticals, Inc.
|
6,902 | $321,012 | |
| 6 | LQDA |
Liquidia Corp
|
3,477 | $277,221 |
All Filings in BCRX
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $281,354 | 29,554 | Shares | Defined | 2026-05-15 | |
| 2025-09-30 | $139,337 | 18,358 | Shares | Defined | 2025-11-14 | |
| 2024-06-30 | $165,265 | 26,742 | Shares | Sole | 2024-08-14 | |
| 2023-12-31 | $111,713 | 18,650 | Shares | Sole | 2024-02-12 | |
| 2023-06-30 | $120,834 | 17,164 | Shares | Sole | 2023-08-10 | |
| No filing history on record for this holder in this stock. | ||||||